47 related articles for article (PubMed ID: 19943918)
1. Feasibility and efficacy of enteral tube feeding on weight stability, lean body mass, and patient-reported outcomes in pancreatic cancer cachexia.
Gresham G; Placencio-Hickok VR; Lauzon M; Nguyen T; Kim H; Mehta S; Paski S; Pandol SJ; Osipov A; Gong J; Jamil LH; Nissen N; Lo SK; Hendifar AE
J Cachexia Sarcopenia Muscle; 2021 Dec; 12(6):1959-1968. PubMed ID: 34609081
[TBL] [Abstract][Full Text] [Related]
2. Early Parenteral Nutrition in Patients with Biliopancreatic Mass Lesions, a Prospective, Randomized Intervention Trial.
Krüger J; Meffert PJ; Vogt LJ; Gärtner S; Steveling A; Kraft M; Mayerle J; Lerch MM; Aghdassi AA
PLoS One; 2016; 11(11):e0166513. PubMed ID: 27861546
[TBL] [Abstract][Full Text] [Related]
3. Routine laboratory parameters to support decision on parenteral nutrition in palliative care.
Kum L; Zeilinger EL; Vohla D; Kitta A; Brunevskaya N; Adamidis F; Ecker F; Masel EK; Mayr-Pirker B; Meyer AL; Sturtzel B; Kreye G; Unseld M
Front Nutr; 2023; 10():1173106. PubMed ID: 38024343
[TBL] [Abstract][Full Text] [Related]
4. In Reply: Randomized Studies Are Needed to Improve Knowledge of Nutritional Interventions for Advanced Cancer Patients.
Bouleuc C; Marchal T; Chvetzoff G; Raynard B; Thiery-Vuillemin A; Aubry R
Oncologist; 2021 Mar; 26(3):e519-e520. PubMed ID: 33426725
[TBL] [Abstract][Full Text] [Related]
5. Impact of cancer cachexia on survival in patients with pancreatic cancer and the efficacy of first-line chemotherapy.
Nishida T; Hosokawa K; Sugimoto A
Int J Clin Oncol; 2024 Jun; ():. PubMed ID: 38831224
[No Abstract] [Full Text] [Related]
6. Nutrition assessment defects in cancer clinical trials.
Aung YM; Aktas A; Shroff V; Kadakia K; Waldman J; Walsh D
BMJ Support Palliat Care; 2023 Nov; ():. PubMed ID: 37940367
[No Abstract] [Full Text] [Related]
7. Under nutrition in cancer: single-centre prospective study.
Ben Kridis W; Khanfir A
BMJ Support Palliat Care; 2023 Dec; ():. PubMed ID: 38135483
[No Abstract] [Full Text] [Related]
8. Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial.
Mitry E; Ducreux M; Ould-Kaci M; Boige V; Seitz JF; Bugat R; Breau JL; Bouché O; Etienne PL; Tigaud JM; Morvan F; Cvitkovic E; Rougier P
Gastroenterol Clin Biol; 2006 Mar; 30(3):357-63. PubMed ID: 16633299
[TBL] [Abstract][Full Text] [Related]
9. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
10. Cachexia and pancreatic cancer: are there treatment options?
Mueller TC; Burmeister MA; Bachmann J; Martignoni ME
World J Gastroenterol; 2014 Jul; 20(28):9361-73. PubMed ID: 25071331
[TBL] [Abstract][Full Text] [Related]
11. An open label randomized multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-FU plus oxaliplatin as 2nd or higher line chemotherapy regarding clinical benefit - PANUSCO.
Märten A; Wente MN; Ose J; Büchler MW; Rötzer I; Decker-Baumann C; Karapanagiotou-Schenkel I; Harig S; Schmidt J; Jäger D
BMC Cancer; 2009 Nov; 9():412. PubMed ID: 19943918
[TBL] [Abstract][Full Text] [Related]
12. Effects of parenteral nutrition + best supportive nutritional care vs. best supportive nutritional care alone on quality of life in patients with pancreatic cancer-a secondary analysis of PANUSCO.
Emanuel A; Rosenberger F; Krampitz J; Decker-Baumann C; Märten A; Jäger D; Rötzer I
Support Care Cancer; 2024 Jun; 32(7):466. PubMed ID: 38935156
[TBL] [Abstract][Full Text] [Related]
13. A randomized multicentre phase II trial comparing adjuvant therapy in patients with interferon alpha-2b and 5-FU alone or in combination with either external radiation treatment and cisplatin (CapRI) or radiation alone regarding event-free survival - CapRI-2.
Märten A; Schmidt J; Ose J; Harig S; Abel U; Münter MW; Jäger D; Friess H; Mayerle J; Adler G; Seufferlein T; Gress T; Schmid R; Büchler MW
BMC Cancer; 2009 May; 9():160. PubMed ID: 19470159
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
